Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.38 |
| ▸ | TUBB | P07437 | 2/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1289874 | 0.85 | ALDH1A1 (0.42) | RAB9AMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL16521356 | 0.84 | TRPA1 (0.42) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL996798 | 0.82 | KDM4E (0.41) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL22187760 | 0.82 | CTSA (0.44) | BRD4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL22864466 | 0.82 | BRD4 (0.38) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL13481179 | 0.80 | IMPDH2 (0.49) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL13380084 | 0.80 | LMNA (0.46) | SMN1; SMN2BRD4LMNANOTUMHPGDS | |
| SCHEMBL3725066 | 0.79 | BRD4 (0.38) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL942521 | 0.78 | HPGDS (0.47) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL16464605 | 0.78 | CSNK2A1 (0.46) | NPC1RAB9AMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| WO-2014057435-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-08 | — | — | US | disclosed |
| EP-0138543-A2 | Silver halide photographic light sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | RNASE1, GTF3C3, CTRL | NPC1 491/4885RAB9A 1251/4885MEN1 4742/4885 |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | NPC1 1248/4885RAB9A 2830/4885MEN1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.